UBS raised the firm’s price target on Nuvalent (NUVL) to $132 from $114 and keeps a Buy rating on the shares. Nuvalent completed its zidesamtinib new drug application submission for 2L+ ROS1+ non-small cell lung cancer in Q3, with potential approval expected by mid-2026, the analyst tells investors in a research note. Pivotal neladalkib data in 2L+ ALK+ NSCLC remain on track for year-end 2025, supported by strong early efficacy signals exceeding those of lolartinib, UBS says. With higher success probabilities for both assets, combined peak sales are now estimated at $3.7B.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent’s Promising Drug Pipeline and Strong Financials Make It a Buy
- Nuvalent price target raised to $112 from $100 at Barclays
- Nuvalent, Inc. Reports Q3 2025 Progress and Financials
- Nuvalent’s Strong Financial Position and Strategic Progress Drive Buy Rating
- Nuvalent reports Q3 EPS ($1.70), consensus ($1.32)